Skip to Content

Pegfilgrastim Dosage

Applies to the following strength(s): 6 mg/0.6 mL

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Neutropenia Associated with Chemotherapy

6 mg subcutaneously once per chemotherapy cycle, beginning 24 to 72 hours after completion of chemotherapy

Usual Pediatric Dose for Neutropenia Associated with Chemotherapy

Based on limited studies:
1 to 12 years old: 100 mcg/kg (maximum dose: 6 mg) once per chemotherapy cycle, beginning 24 to 72 hours after completion of chemotherapy

13 to 18 years old and greater than 45 kg: 6 mg once per chemotherapy cycle, beginning 24 to 72 hours after completion of chemotherapy

Renal Dose Adjustments

No adjustment is necessary.

Liver Dose Adjustments

Data not available

Precautions

Pegfilgrastim is contraindicated in patients with known hypersensitivity to E. coli-derived proteins.

Pegfilgrastim should not be administered in the period between 14 days before and 24 hours after the administration of cytotoxic chemotherapy.

Splenic rupture has been reported rarely following the administration of filgrastim, the parent compound of pegfilgrastim, when used for peripheral blood progenitor cell (PBPC) mobilization in both healthy donors and patients with cancer. Pegfilgrastim has not been evaluated in this setting, therefore, should not be used for PBPC mobilization. Patients receiving pegfilgrastim who report left upper abdominal or shoulder tip pain should be evaluated for an enlarged spleen or splenic rupture.

Adult respiratory distress syndrome (ARDS) has been reported with the use of filgrastim, therefore, patients receiving pegfilgrastim who develop fever, lung infiltrates, or respiratory distress should be evaluated for the possibility of ARDS.

Although allergic-type reactions were not observed during clinical trials of pegfilgrastim, some cases related to the administration of the parent compound, filgrastim, have been reported. If a serious allergic reaction or an anaphylactic reaction occurs with the use of pegfilgrastim, appropriate therapy should be administered and further use of pegfilgrastim should be discontinued.

Patients with sickle cell disease who receive pegfilgrastim should be kept well hydrated and monitored for the occurrence of sickle cell crisis.

Dialysis

Data not available

Other Comments

According to the NCCN guidelines, efficacy has been demonstrated with every 2-week chemotherapy regimens. Benefit has not been demonstrated with regimens less than 2-weeks in duration.

The 6 mg fixed dose formulation should not be used in infants, children, and smaller adolescents weighing less than 45 kg.

Hide